Alumis Inc.
ALMS
Rang în acțiuni
#9977
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Preț acțiune
$6.69
Ultima sincronizare: 2026-10-20
Capitalizare de piață
$865.92M
Schimbare (1 zi)
5.52%
Schimbare (1 an)
194.71%
Țară
US
Tranzacționează Alumis Inc. (ALMS)
Categorie
Healthcare
Venituri pentru Alumis Inc. (ALMS)
Venituri în Mar 2025 TTM: $342.00K
Conform celor mai recente rapoarte financiare ale Alumis Inc., venitul actual al companiei (TTM) este $342.00K. În anul 2023, compania a avut un venit de 0.00 egal cu venitul din anul 2022, care a fost de 0.00. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Alumis Inc. din 2021 până în 2026
Venituri la sfârșitul fiecărui an
| An | Venituri | Schimbă |
|---|---|---|
| 2026 (TTM) | $342.00K | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
Venituri pentru companii similare sau concurente
| Companie | Venituri | Diferență de venituri | Țara |
|---|---|---|---|
| $12.62B | 3,691,215.79% |
US
|
|
| $2.23B | 651,361.99% |
US
|
|
| $15.74B | 4,603,504.43% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 1,760,510.32% |
NL
|
